Inactive Instrument

Antares Pharma, Inc.

Equities

ATRS

US0366421065

Medical Equipment, Supplies & Distribution

Antares Pharma Announces Executive Changes

June 24, 2014 at 09:00 am EDT

Antares Pharma Inc. announced the resignation of Paul K. Wotton, Ph.D. who informed the Company's Board of Directors that he will assume the position of chief executive officer of a development stage biotechnology company. Dr. Wotton also has resigned from the Antares Board of Directors. The company also announced the appointment of Eamonn P. Hobbs to the position of President and Chief Executive Officer of the company effective immediately.

Mr. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Mr. Hobbs was previously the President and Chief Executive Officer of Delcath Systems Inc.

Latest news about Antares Pharma, Inc.

Antares Pharma, Inc. Announces Management Changes	22-05-24	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from NASDAQ Composite Index	22-05-24	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Pharmaceuticals Select Industry Index	22-05-24	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Global BMI Index	22-05-24	CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P TMI Index	22-05-24	CI
Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..	22-05-22	CI
Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition	22-05-12	MT
Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares	22-04-26	MT
Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy	22-04-14	MT
HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60	22-04-14	MT
Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6	22-04-14	MT
Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy	22-04-14	MT
Sector Update: Health Care Stocks Putting Up Modest Gains This Afternoon	22-04-13	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	22-04-13	DJ
Sector Update: Health Care Stocks Edging Higher Wednesday Afternoon	22-04-13	MT
Top Midday Gainers	22-04-13	MT
Truist Securities Downgrades Antares Pharma to Hold From Buy, Adjusts PT to $5.60 From $7.00	22-04-13	MT
Halozyme to Acquire Antares Pharma for $960 Million; Antares Shares Surge	22-04-13	MT
Wall Street Set for Muted Open as Traders Digest BlackRock, JPMorgan Earnings; Producer Prices Rise More Than Expected	22-04-13	MT
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	22-04-13	MT
Top Premarket Gainers	22-04-13	MT
North American Morning Briefing: Stock Futures Tick Up Ahead of Earnings	22-04-13	DJ
Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Antares Pharma, Inc. for $970 million.	22-04-12	CI
Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy	22-03-29	MT

Chart Antares Pharma, Inc.

Duration

Period

More charts

Company Profile

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.82%	182B
MEDTRONIC PLC	+1.38%	111B
BECTON, DICKINSON AND COMPANY	-2.82%	68.48B
DEXCOM, INC.	+0.69%	49.69B
CENCORA, INC.	+8.54%	44.46B
HOYA CORPORATION	+2.33%	40.67B
METTLER-TOLEDO INTERNATIONAL, INC.	+20.50%	31.22B
WEST PHARMACEUTICAL SERVICES, INC.	+1.72%	26.09B
TERUMO CORPORATION	+15.30%	25.32B

Other Medical Equipment, Supplies & Distribution